Search results
Is It Too Late to Buy Pfizer Stock? | The Motley Fool
The Motley Fool· 5 days agoAre Pfizer's (PFE -0.43%) best days behind it? If the stock's critics are to be believed, the answer...
Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Market Watch· 1 day ago“We’ll provide protection that’s broader than anything that’s out there,” Art Hirt, senior vice...
7,403 Shares in Pfizer Inc. (NYSE:PFE) Bought by Gerber LLC
ETF DAILY NEWS· 2 days agoGerber LLC bought a new position in Pfizer Inc. (NYSE:PFE – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 7,403 shares of the biopharmaceutical ...
Pfizer (NYSE:PFE) Stock Price Down 0.9%
ETF DAILY NEWS· 4 days agoPfizer Inc. (NYSE:PFE – Get Free Report) was down 0.9% during trading on Thursday . The company traded as low as $27.20 and last traded at $27.41. Approximately 11,513,196 ...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 6 days agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
MSD competes with Pfizer in pneumococcal vaccine market after FDA approval
Pharmaceutical Technology via Yahoo Finance· 12 hours agoThis includes the eight unique serotypes, 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B compared to other...
Wahed Invest LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoWahed Invest LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 8.6% during the 4th quarter, according to its most recent disclosure with the Securities ...
Pfizer's COVID-19 Vaccine Safety Claims Under Lens, Faces Lawsuit From Kansas For Alleged Misleading...
Benzinga· 1 day agoThe state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoPfizer disclosed on May 7 that a child participating in another...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 5 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...